Chapter 84 Strabismus
non-surgical treatment
Optical correction
It is important to recognize that refractive errors, whether corrected or uncorrected, have a major impact on strabismus and its management. Correcting a refractive error may result in better control of a misalignment solely by gaining optimal visual acuity. Conversely, previously uncorrected strabismus patients can be made symptomatic by correcting their refractive error by encouraging spontaneous alternation or switch of fixation to their non-dominant eye.1
All children with strabismus or suspected strabismus require a cycloplegic refraction to determine the basic refractive state without the influence of accommodation. This can be done with 0.5% to 2% cyclopentolate (Mydrilate, Cyclogyl), 1% tropicamide (Mydriacyl), or 1% atropine. Cyclopentolate is commonly preferred over atropine due to its shorter onset and duration of action. The mean residual accommodation of these agents is less than 0.1 D for a 3-day administration of 1% atropine, and between 0.4 and 0.6 D for 1% cyclopentolate or 1% tropicamide in children with dark irides.2 The difference between atropine and cyclopentolate cycloplegia has consistently been measured to be between 0.4 and 0.7 D,2–5 but it is important to recognize that 15−20% of children who have a cycloplegic refraction with 1% cyclopentolate alone will have a hyperopic undercorrection of 1 D or more.2–3 Therefore, in accommodative esotropia with a residual deviation, an atropine refraction is still essential to uncover the maximal amount of hyperopia that needs to be corrected. Atropine eye drops do not sting: cyclopentolate drops do. The pupillary dilation achieved with any of these agents allows the funduscopic exam which is mandatory during the initial evaluation of a strabismus patient to exclude visual axis opacification or abnormalities of the posterior segments.
Considering the optimal optical correction for each patient is essential in the management of their strabismus. In acquired esotropia, particularly accommodative esotropia, all degrees of hypermetropia may be significant, and should be fully corrected with spectacles. The full hyperopic correction should be prescribed in order to remove all accommodative convergence. In most forms of esotropia (including essential infantile esotropia) following surgical alignment, spectacle correction may be of considerable value in improving a small residual deviation. In patients with surgical overcorrections of partially accommodative esotropia, reduction of the hypermetropic correction of more than +2.50 D may be associated with long-term instability of the alignment: such overcorrections should be avoided.6,7
In intermittent exotropia (X(T)), it may seem logical not to correct moderate to high hypermetropia since the convergence induced by the hypermetropia has a beneficial effect on the control of the exodeviation. A small study of children with moderate to high hyperopia (3−7 D) and X(T) showed that full hyperopic prescription corrected the manifest deviation and improved the binocular status in all the patients.8 A larger study demonstrated that with partial spectacle correction the mean exodeviation increased on average 10 PD (prism diopters) in one-third of patients with X(T) and moderate hyperopia compared to patients with fully corrected hyperopia, emmetropia, or myopia.9 Nevertheless, high hyperopia, anisometropia, significant astigmatism, and myopia should always be corrected in patients with X(T). High hyperopic patients may not be accommodating fully and experiencing blur, resulting in poor control of the X(T). It is unclear if moderate hyperopia needs to be corrected unless the patient has decreased vision, or if surgical planning should be done wearing moderate hyperopic corrections to improve long-term surgical outcomes.9
For the treatment of X(T), over-minus lens therapy has been proposed (1.5−4 D additional minus) to stimulate accommodative convergence and improve control of the deviation. In three prospective studies of children treated with over-minus glasses, some form of improvement (depending on the outcome measure used) was seen in 45−70% of patients.10–12 This improvement was seen irrespective of the initial angle of deviation and in some patients was maintained after discontinuation of therapy. Since the reports on the natural history and spontaneous improvement of X(T) are contradictory, and there is a lack of control groups for these interventions, it is difficult to ascertain their real efficacy. Over-minus therapy does not appear to increase myopia.12,13
Other non-surgical interventions prescribed for the treatment of X(T) include part-time occlusion, fusional vergence exercises, and atropine. The rationale behind these interventions is that they may improve the control of the intermittent deviation, preserve stereoacuity and eliminate, or at least delay, surgical treatment. Most of these interventions have not been rigorously studied and their efficacy remains unclear.14,15 (see section on Occlusion therapy).
Occlusion therapy
Some authorities recommend treating amblyopia fully before strabismus surgery even though in some cases this means delaying surgery for many months. Two prospective studies evaluated the need for completion of amblyopia therapy versus early operation with continuation of occlusion postoperatively. Neither study detected a significant difference in motor or sensory outcome whether amblyopia was fully or only partially treated before surgery.16,17
A recent study reported that, with partially accommodative esotropia, the mean angle of deviation decreased significantly after occlusion treatment for amblyopia and noticed that occlusion may resolve the non-accommodative component of the deviation obviating the need for surgery. Surgery would have been performed in 81% of patients if planned before the termination of amblyopia treatment, compared to 38% of patients that ultimately required surgery.18 Another study showed that 61% of 46 small-angle strabismic children 1.5 to 9 years of age, undergoing part-time treatment with Bangerter foils for amblyopia, developed motor fusion with no additional interventions.19
Occlusion therapy, even in the absence of amblyopia, may be effective in improving the control of some forms of strabismus. Part-time (3−4 hours a day) unilateral or alternating occlusion is commonly prescribed for the treatment of X(T).20,21 Occlusion may improve the control of the deviation by eliminating suppression. Commonly, the angle of the deviation decreases, and the relationship between distance and near deviation may change, altering the X(T)pattern.21 Unfortunately, most data supporting this and other non-surgical treatments for X(T) come from small retrospective and/or non-controlled studies. It remains unclear what is the most effective treatment for this condition.14
Orthoptic exercises/vision therapy
Orthoptic exercises are sometimes used to teach patients how to use their fusion ability more efficiently. Orthoptic exercises may help in establishing control of strabismus in a very small group of patients with good fusion potential. The effectiveness of orthoptic exercises (and the broader practice of vision therapy) in treating most forms of strabismus is debated. A comprehensive review of the evidence supporting orthoptic exercises/vision therapy from the UK concluded that there was little evidence-based research to support these practices.22 A notable exception is the management of convergence insufficiency.23
The Convergence Insufficiency Treatment Trial, a placebo-controlled randomized clinical trial, demonstrated that a 12-week office-based program of vergence and accommodative exercises (such as string-convergence and barrel-convergence) with home reinforcement was more effective than home-based “pencil push-ups,” home-based computer therapy plus “pencil push-ups,” or office-based placebo therapy in treating convergence insufficiency in children.24 A similar conclusion was reached by the same researchers investigating convergence insufficiency treatment in young adults.25
Drugs
Botulinum toxin
The mechanism by which permanent alignment can occur after the paralyzing effect of botulinum toxin is gone is not completely understood. One theory is that if the antagonist muscle remains contracted for a certain time because of reduced force in treated muscle, it will develop structural alterations that shorten it26,27 and decrease its elasticity (contracture). Conversely, the chemodenervated muscle will undergo lengthening as its antagonist contracts. This length adaptation is believed to occur through the addition and deletion of sarcomeres.27 The alterations induced in extraocular muscles by botulinum treatment have been shown to be specific to the orbital singly innervated muscle fibers.26,28